Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

被引：8

作者：

Ahn, M. ^{[1
]}

Cho, B. C. ^{[2
]}

Siena, S. ^{[3
]}

Drilon, A. ^{[4
]}

De Braud, F. ^{[5
]}

Krebs, M. ^{[6
,7
]}

John, T. ^{[8
]}

Karapetis, C. ^{[9
]}

Johnson, A. ^{[10
]}

Chow-Maneval, E. ^{[11
]}

Multani, P. ^{[11
]}

Doebele, R. ^{[12
]}

机构：

[1] Samsung Med Ctr, Dept Med, Div Hematol Oncol, Seoul, South Korea

[2] Yonsei Univ, Div Med Oncol, Coll Med, Seoul, South Korea

[3] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Hematol & Oncol, Milan, Italy

[4] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[6] Univ Manchester, Christie NHS Fdn Trust, Expt Canc Med Team, Manchester, Lancs, England

[7] Christie NHS Fdn Trust, Manchester, Lancs, England

[8] Austin Hlth, Olivia Newton John Canc Ctr, Melbourne, Vic, Australia

[9] Flinders Med Ctr, Bedford Pk, SA, Australia

[10] Ignyta, Data Sci, San Diego, CA USA

[11] Ignyta, Clin Dev, San Diego, CA USA

[12] Univ Colorado, Div Med Oncol, Aurora, CO USA

来源：

关键词：

entrectinib; ros1; NSCLC;

D O I：

10.1016/j.jtho.2017.09.411

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA 14.06

引用

页码：S1783 / S1783

页数：1